Literature DB >> 17404159

Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota.

Carolyn S P Lam1, Véronique L Roger, Richard J Rodeheffer, Francesca Bursi, Barry A Borlaug, Steve R Ommen, David A Kass, Margaret M Redfield.   

Abstract

BACKGROUND: Mechanisms purported to contribute to the pathophysiology of heart failure with normal ejection fraction (HFnlEF) include diastolic dysfunction, vascular and left ventricular systolic stiffening, and volume expansion. We characterized left ventricular volume, effective arterial elastance, left ventricular end-systolic elastance, and left ventricular diastolic elastance and relaxation noninvasively in consecutive HFnlEF patients and appropriate controls in the community. METHODS AND
RESULTS: Olmsted County (Minn) residents without cardiovascular disease (n=617), with hypertension but no heart failure (n=719), or with HFnlEF (n=244) were prospectively enrolled. End-diastolic volume index was determined by echo Doppler. End-systolic elastance was determined using blood pressure, stroke volume, ejection fraction, timing intervals, and estimated normalized ventricular elastance at end diastole. Tissue Doppler e' velocity was used to estimate the time constant of relaxation. End-diastolic volume (EDV) and Doppler-derived end-diastolic pressure (EDP) were used to derive the diastolic curve fitting (alpha) and stiffness (beta) constants (EDP=alphaEDVbeta). Comparisons were adjusted for age, sex, and body size. HFnlEF patients had more severe renal dysfunction, yet smaller end-diastolic volume index and cardiac output and increased EDP compared with both hypertensive and healthy controls. Arterial elastance and ventricular end-systolic elastance were similarly increased in hypertensive controls and HFnlEF patients compared with healthy controls. In contrast, HFnlEF patients had more impaired relaxation and increased diastolic stiffness compared with either control group.
CONCLUSIONS: From these cross-sectional observations, we speculate that the progression of diastolic dysfunction plays a key role in the development of heart failure symptoms in persons with hypertensive heart disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17404159      PMCID: PMC2001291          DOI: 10.1161/CIRCULATIONAHA.106.659763

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

1.  Defining diastolic heart failure: a call for standardized diagnostic criteria.

Authors:  R S Vasan; D Levy
Journal:  Circulation       Date:  2000-05-02       Impact factor: 29.690

2.  Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study.

Authors:  S R Ommen; R A Nishimura; C P Appleton; F A Miller; J K Oh; M M Redfield; A J Tajik
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

3.  Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction.

Authors:  Vojtech Melenovsky; Barry A Borlaug; Boaz Rosen; Ilan Hay; Luigi Ferruci; Christopher H Morell; Edward G Lakatta; Samer S Najjar; David A Kass
Journal:  J Am Coll Cardiol       Date:  2006-12-29       Impact factor: 24.094

4.  Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure.

Authors:  Dalane W Kitzman; William C Little; Peter H Brubaker; Roger T Anderson; W Gregory Hundley; Christian T Marburger; Bridget Brosnihan; Timothy M Morgan; Kathryn P Stewart
Journal:  JAMA       Date:  2002-11-06       Impact factor: 56.272

5.  Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria.

Authors:  Horng H Chen; John G Lainchbury; Michele Senni; Kent R Bailey; Margaret M Redfield
Journal:  J Card Fail       Date:  2002-10       Impact factor: 5.712

6.  Noninvasive single-beat determination of left ventricular end-systolic elastance in humans.

Authors:  C H Chen; B Fetics; E Nevo; C E Rochitte; K R Chiou; P A Ding; M Kawaguchi; D A Kass
Journal:  J Am Coll Cardiol       Date:  2001-12       Impact factor: 24.094

7.  Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations.

Authors:  Miho Kawaguchi; Ilan Hay; Barry Fetics; David A Kass
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

8.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

Authors:  Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

9.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle.

Authors:  Michael R Zile; Catalin F Baicu; William H Gaasch
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

10.  Left atrial volume as an index of left atrial size: a population-based study.

Authors:  Allison M Pritchett; Steven J Jacobsen; Douglas W Mahoney; Richard J Rodeheffer; Kent R Bailey; Margaret M Redfield
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

View more
  167 in total

1.  Heart failure with a normal ejection fraction: treatments for a complex syndrome?

Authors:  Samuel Bernard; Mathew S Maurer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

2.  Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo.

Authors:  Kalkidan Bishu; Nazha Hamdani; Selma F Mohammed; Martina Kruger; Tomohito Ohtani; Ozgur Ogut; Frank V Brozovich; John C Burnett; Wolfgang A Linke; Margaret M Redfield
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

3.  Congestion is the driving force behind heart failure.

Authors:  Maya Guglin
Journal:  Curr Heart Fail Rep       Date:  2012-09

4.  Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction.

Authors:  Tomohito Ohtani; Selma F Mohammed; Kazuhiro Yamamoto; Shannon M Dunlay; Susan A Weston; Yasushi Sakata; Richard J Rodeheffer; Veronique L Roger; Margaret M Redfield
Journal:  Eur Heart J       Date:  2012-05-29       Impact factor: 29.983

5.  HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis.

Authors:  Ludivine Renaud; Lillianne G Harris; Santhosh K Mani; Harinath Kasiganesan; James C Chou; Catalin F Baicu; An Van Laer; Adam W Akerman; Robert E Stroud; Jeffrey A Jones; Michael R Zile; Donald R Menick
Journal:  Circ Heart Fail       Date:  2015-09-14       Impact factor: 8.790

Review 6.  Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

Authors:  Fayez El Shear
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

7.  Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis.

Authors:  Michael R Zile; Catalin F Baicu; Robert E Stroud; An Van Laer; Jazmine Arroyo; Rupak Mukherjee; Jeffrey A Jones; Francis G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-27       Impact factor: 4.733

Review 8.  Ventricular remodeling in heart failure with preserved ejection fraction.

Authors:  Amil M Shah
Journal:  Curr Heart Fail Rep       Date:  2013-12

9.  Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy.

Authors:  Mathew S Maurer; Sergio Teruya; Bibhas Chakraborty; Stephen Helmke; Donna Mancini
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

10.  Treatment of heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.